Today assays are available to detect a humoral immune response against alpha-methyl-acyl-CoA racemase, which may have the potential to complement PSA screening in identifying patients with clinically significant prostate cancer (Sreekumar et al. 2004). The gene discussed is KLK3; the disease is prostate carcinoma.